Pharmaceuticals, Biotechnology and Life Sciences
LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for pa…
ATLANTA–(BUSINESS WIRE)–Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced toda…
ATLANTA–(BUSINESS WIRE)–Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced toda…
– Significant progress achieved across pipeline of Bicycle® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™)
– Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milesto…
– Significant progress achieved across pipeline of Bicycle® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™)
– Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milesto…
– Significant progress achieved across pipeline of Bicycle® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™)
– Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milesto…
– Significant progress achieved across pipeline of Bicycle® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™)
– Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milesto…
– Significant progress achieved across pipeline of Bicycle® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™)
– Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milesto…
CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today a…
CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today a…